Variable | SIE-BCS (N = 63) | C-BCS (N = 117) | p value |
---|---|---|---|
Age (years) | 0.961 | ||
Mean | 52.8 ± 8.7 | 54.0 ± 10.4 | |
Range | 35.0–66.0 | 19.0–70.0 | |
Premenopausal, n (%) | 24 (38.1%) | 41 (35.0%) | 0.770 |
Neoadjuvant chemotherapy, n (%) | 7 (11.1%) | 10 (8.5%) | 0.381 |
cTNM stage, n (%) | 0.510 | ||
I | 32 (50.8%) | 49 (41.9%) | |
IIA | 22 (34.9%) | 47 (40.1%) | |
IIB | 9 (14.3%) | 21 (18.0%) | |
PR, n (%) | 0.061 | ||
Positive | 47 (74.6%) | 71 (60.7%) | |
Negative | 16 (25.4%) | 46 (39.3%) | |
ER, n (%) | 0.619 | ||
Positive | 51 (80.9%) | 91 (77.8%) | |
Negative | 12 (19.1%) | 26 (22.2%) | |
HER2, n (%) | 0.011 | ||
Positive | 5 (7.9%) | 27 (23.1%) | |
Negative | 58 (92.1%) | 90 (76.9%) | |
Tumor location, n (%) | 0.285 | ||
Lateral upper quadrant | 42 (66.7%) | 67 (57.3%) | |
Lateral lower quadrant | 2 (3.2%) | 8 (6.8%) | |
Medial upper quadrant | 17 (26.9%) | 31 (26.5%) | |
Medial lower quadrant | 2 (3.2%) | 11 (9.4%) | |
SLNB or ALND, n (%) | 0.452 | ||
SLNB only | 49 (77.8%) | 85 (72.6%) | |
SLNB and ALND | 14 (22.2%) | 32 (27.4%) | |
pT staging, n (%) | 0.672 | ||
pT1 | 45 (71.4%) | 80 (73.8%) | |
pT2 | 18 (28.6%) | 37 (26.2%) | |
pN staging, n (%) | 0.517 | ||
pN0 | 46 (73.0%) | 80 (68.4%) | |
pN1 | 17 (27.0%) | 37 (31.6%) | |
Degree of tumor differentiation, n (%) | 0.930 | ||
G1 | 6 (9.5%) | 12 (10.3%) | |
G2 | 52 (82.5%) | 94 (80.3%) | |
G3 | 5 (8.0%) | 11 (9.4%) | |
Tumor type, n (%) | 0.731 | ||
Invasive ductal carcinoma | 54 (85.7%) | 102 (87.2%) | |
Mucinous carcinoma | 3 (4.8%) | 3 (2.6%) | |
Preinvasive carcinoma | 6 (9.5%) | 12 (10.2%) | |
Tumor size (cm) | 0.440 | ||
Mean | 1.90 ± 0.7 | 1.95 ± 0.8 | |
Range | 0.60–3.20 | 0.60–4.00 |